Literature DB >> 26567285

Antifungal-Associated Drug-Induced Cardiac Disease.

John D Cleary1, Kayla R Stover2.   

Abstract

The etiology of cardiomyopathies are classified into 4 main groupings (dilated, hypertrophic, restrictive, and idiopathic) and can be mechanistically caused by myocarditis, conduction abnormalities, focal direct injury, or nutritional deficiency. Based on our review of this topic, evidence suggests that echinocandin-related cardiac dysfunction is a mitochondrial drug-induced disease caused by focal direct myocyte injury. With caspofungin or anidulafungin administration into the heart via central line, exposure is likely extreme enough to induce the acute toxicity. Chronic or low-dose exposure may lead to hypertrophic cardiomyopathy; however, only acute exposures have been explored to date.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cardiac output; cardiac toxicity; echinocandin; echocardiography

Mesh:

Substances:

Year:  2015        PMID: 26567285     DOI: 10.1093/cid/civ739

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

2.  Hemodynamic changes in surgical intensive care unit patients undergoing echinocandin treatment.

Authors:  Christian Koch; Emmanuel Schneck; Christoph Arens; Melanie Markmann; Michael Sander; Michael Henrich; Markus A Weigand; Christoph Lichtenstern
Journal:  Int J Clin Pharm       Date:  2019-11-21

3.  Caspofungin Modulates Ryanodine Receptor-Mediated Calcium Release in Human Cardiac Myocytes.

Authors:  Christian Koch; Jennifer Jersch; Emmanuel Schneck; Fabian Edinger; Hagen Maxeiner; Florian Uhle; Markus A Weigand; Melanie Markmann; Michael Sander; Michael Henrich
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

4.  Cardiac Safety of High-dose Micafungin.

Authors:  Kayla R Stover; John D Cleary
Journal:  J Pharmacol Pharmacother       Date:  2017 Jul-Sep

5.  Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia.

Authors:  Roya Sattarzadeh Badkoubeh; Mostafa Farajpour; Mohammadreza Salehi; Alborz Sherafati; Zahra Zamani; Omid Rezahosseini; Pejman Mansouri; Akram Sardari
Journal:  Toxics       Date:  2022-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.